PMID- 11310855
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20191210
IS  - 0741-5400 (Print)
IS  - 0741-5400 (Linking)
VI  - 69
IP  - 4
DP  - 2001 Apr
TI  - MCP-1 receptor binding affinity is up-regulated by pre-stimulation with MCP-1 in 
      an actin polymerization-dependent manner.
PG  - 666-74
AB  - Monocyte chemoattractant protein-1 (MCP-1) induces monocyte chemotaxis via 
      interaction with the MCP-1 receptor CCR2. We found that MCP-1 binding to 
      monocytic THP-1 cells was increased by pre-treatment with MCP-1. The amount of 
      CCR2 mRNA and the cell-surface expression of CCR2 were not affected by MCP-1 
      stimuli. In contrast, the MCP-1-treated THP-1 cells showed a sixfold increase in 
      MCP-1 binding affinity compared with untreated cells. MCP-1 binding to 
      CCR2B-transfected HEK-293 cells was also enhanced by pre-treatment with MCP-1, 
      and MCP-1 binding affinity increased by sixfold. In both cell lines, the 
      enhancement of MCP-1 binding by stimulation with MCP-1 was blocked by 
      cytochalasin D, an inhibitor of actin polymerization. This effect of 
      pre-treatment with MCP-1 is insensitive to pertussis toxin and partially blocked 
      by U73122, an inhibitor of phospholipase C. These results demonstrate that the 
      MCP-1 receptor binding affinity is up-regulated by MCP-1 stimuli in an actin 
      polymerization-dependent manner.
FAU - Kito, K
AU  - Kito K
AD  - New Product Research Laboratories II, Daiichi Pharmaceutical Company Ltd., Tokyo, 
      Japan. kitok7m2@daiichipharm.co.jp
FAU - Morishita, K
AU  - Morishita K
FAU - Nishida, K
AU  - Nishida K
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Leukoc Biol
JT  - Journal of leukocyte biology
JID - 8405628
RN  - 0 (Actins)
RN  - 0 (Androstadienes)
RN  - 0 (Biopolymers)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Estrenes)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Pyrrolidinones)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Virulence Factors, Bordetella)
RN  - 112648-68-7 
      (1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione)
RN  - 3CHI920QS7 (Cytochalasin B)
RN  - EC 2.4.2.31 (Pertussis Toxin)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 3.1.4.- (Type C Phospholipases)
RN  - EC 3.6.1.- (GTP-Binding Proteins)
RN  - EC 4.6.1.13 (Phosphatidylinositol Diacylglycerol-Lyase)
RN  - H88EPA0A3N (Staurosporine)
RN  - XVA4O219QW (Wortmannin)
SB  - IM
MH  - Actins/*metabolism
MH  - Androstadienes/pharmacology
MH  - Biopolymers
MH  - Cell Line
MH  - Chemokine CCL2/*pharmacology
MH  - Chemotaxis/*drug effects
MH  - Cytochalasin B/pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - Estrenes/pharmacology
MH  - GTP-Binding Proteins/antagonists & inhibitors/physiology
MH  - Humans
MH  - Macromolecular Substances
MH  - Monocytes/drug effects/metabolism
MH  - Pertussis Toxin
MH  - Phosphatidylinositol Diacylglycerol-Lyase
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Polymerase Chain Reaction
MH  - Protein Binding/drug effects
MH  - Protein Kinase C/antagonists & inhibitors
MH  - Pyrrolidinones/pharmacology
MH  - Receptors, CCR2
MH  - Receptors, Chemokine/*drug effects/genetics/metabolism
MH  - Recombinant Fusion Proteins/metabolism
MH  - Recombinant Proteins/pharmacology
MH  - Signal Transduction/drug effects
MH  - Staurosporine/pharmacology
MH  - Transcription, Genetic/drug effects
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Type C Phospholipases/antagonists & inhibitors/physiology
MH  - Virulence Factors, Bordetella/pharmacology
MH  - Wortmannin
EDAT- 2001/04/20 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/04/20 10:00
PHST- 2001/04/20 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/04/20 10:00 [entrez]
PST - ppublish
SO  - J Leukoc Biol. 2001 Apr;69(4):666-74.